Consortium

FLUNIVAC brings together a group of partners from four different European member states (the Netherlands, Belgium, Germany and Sweden) that combined have the required expertise necessary to achieve its ambitious goals. Each partner is a well-recognized expert or entity in the respective area of research involved for the completion of the project. Bringing these experts together in the FLUNIVAC consortium results in a strong symbiosis that can excel in universal influenza vaccine development from ‘lab bench’ to ‘bedside’.

Erasmus Universitair Medisch Centrum Rotterdam (EMC) Department of Viroscience: Guus Rimmelzwaan (coordinator)

Artemis One Health Research BV (Artemis): Ab Osterhaus, Eric Claassen

Ludwig-Maximilians-Universität München (LMU) Institute for infection medicine and zoonoses: Gerd Sutter

AIMM Therapeutics BV (AIMM): Hergen Spits, Tim Beaumont

ProBioGen AG: Ingo Jordan, Volker Sandig

VIB: Xavier Saelens

ISCONOVA (NOVAVAX): Karin Lövgren Bengtsson, Linda Stertman

Q-Biologicals: Annie Van Broekhoven, Bosman Fons

Flunivac expertise

 

 

Rationale

Flunivac’s approach

Results

First periodic report